The incidence of T1D is increasing in the U.S. by 3–5% per year
and often children are not diagnosed before clinical symptoms
of T1D are present

The goal of this series is to increase awareness of the indications and expected outcomes of Tzield (teplizumab) while emphasizing the importance of early screening for type 1 diabetes (T1D) associated autoantibodies, particularly in individuals with heightened familial risk-factors. The four-session series will explain the benefits and risks of screening for early T1D and summarize how appropriate follow-up of a person who screens positive for early T1D is essential to preventing diabetic ketoacidosis at disease onset. Additionally, we'll discuss which stages of T1D have FDA-approved treatment options other than insulin as well as the clinical treatment options for patients with early T1D. Learn from experts in the field about how to incorporate these tools into your practice in order to gain confidence and improve care for your patients.

Benefits of Screening for Early Type 1 Diabetes

Audience:
Primary care, family medicine and pediatric physicians, NPs and PAs; diabetes educators (CDEs); pediatric and adult endocrinologists and APPs in Colorado and Wyoming

Commitment:
Four weekly ECHO sessions held virtually

In Partnership With:

Barbara Davis Center for Childhood Diabetes

  • ECHO SESSION 1

    Screening

    April 11, 2024

  • ECHO SESSION 2

    Monitoring/Follow-up

    April 18, 2024

  • ECHO SESSION 3

    Staging/Early Type 1 Diabetes Clinic

    April 25, 2024

  • ECHO SESSION 4

    Early Treatment Options

    May 2, 2024

Contact ECHO Colorado